Inside the secondary analysis, the considerably less conservative but clinically meaningful criterion of secure response (described being a 50% or more reduction in MADRS from baseline for 2 weeks) was used. In the patients who attained secure response, twenty five.eight% from the esketamine group and 57.6% from the placebo group relapsed, with a m